Loading...
Rapid, Accurate Test Results in ~30-minutes
Test, diagnose and treat in a single visit with the first and only FDA-cleared, CLIA-waived, point-of-care platform for CT/NG testing for males and females.
Together, we can help stop the spread
STIs are on the rise and testing pathways are struggling to keep up.
Traditional pathway
Sample sent to central reference laboratory
1-10 days
Treatment may be potentially inappropriate, before leaving the clinic
binx io pathway
Sample ran on binx io point-of-care test
~30 mins
Increases treatment compliance with same visit test and treatment
--The power of a central lab at the touch of a button--
The FDA-cleared, CLIA-waived, binx io platform uses ultra-rapid polymerase chain reaction (PCR) amplification in conjunction with binx health’s proprietary electrochemical detection to achieve sensitivity and specificity equivalent to central lab performance.
Clinically-Proven, FDA-Cleared
Clinical performance measured against three FDA-cleared standard-of-care molecular platforms
| Target | Sensitivity | Specificity |
|---|---|---|
| Chlamydia | 96.1% | 99.1% |
| Gonorrhea | 100.0% | 99.9% |
| Target | Sensitivity | Specificity |
|---|---|---|
| Chlamydia | 92.5% | 99.3% |
| Gonorrhea | 97.3% | 100.0% |
| Female | Male | |||||
|---|---|---|---|---|---|---|
| Target | Sensitivity | Specificity | Sensitivity | Specificity | ||
| Chlamydia | 96.1% | 99.1% | 92.5% | 99.3% | ||
| Gonorrhea | 100.0% | 99.9% | 97.3% | 100.0% |
2,445 person (1,523 females; 992 males) multi-center clinical study As published in JAMA Network Open Van Der Pol, B. et al. Evaluation of the Performance of a Point-of-Care Test for Chlamydia and Gonorrhoea. JAMA Network Open 3(5) (2020): e204819
How it works
Learn how the binx io is transforming diagnostics with rapid results at the point-of-care
Ready to Bring STI Testing to Your Community?
Learn how the binx io can improve your community health outcomes and drive revenue for your clinic today.
